Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
Holding LYEL?
Track your performance easily
LYEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.09 - $3.26
Previous Close$1.35
Volume1.50M
Average Volume (3M)918.94K
Market Cap
$345.60M
Enterprise Value-$92.19M
Total Cash (Recent Filing)$491.12M
Total Debt (Recent Filing)$53.32M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 05, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding256,003,113
10 Day Avg. Volume593,410
30 Day Avg. Volume918,943
Standard Deviation0.25
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.61
Price to Sales (P/S)6589.71
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.71K
Enterprise Value/Gross Profit-709.17
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$3.67Price Target Upside135.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma’s Promising CAR T-Cell Therapy Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical DataThe major catalyst for Lyell will be LYL845 data in melanoma.
Efficacy SignalsThere were encouraging, albeit early, signals of efficacy, including signs of dose-dependent activity in r/r TNBC patients, with 2/6 dosed experiencing confirmed partial responses.
Financial PerformanceLyell ended 2Q24 with $491M in cash, which management expects to provide an operational runway into 2027.
Bears Say
Adverse EventsCommon Grade 3+ adverse events included pneumonitis, which resulted in a death, leading to dosing down-titration for those with lung involvements.
Clinical Trial ResultsOf greatest importance, each of the two PRs lasted at most three months before progression, which we believe is not sufficient durability to constitute clinically meaningful activity.
Safety ConcernsThere was widespread pneumonitis observed in patients with lung involvement, leading to an instance of Grade 5 respiratory failure.
---
Ownership Overview
43.81% Insiders
12.43% Mutual Funds
37.79% Other Institutional Investors
5.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $1.09 and its highest was $3.25 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Currently, no data Available
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Aug 07, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.198 by $0.018.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -$0.2.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 256,003,100 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.198. Following the earnings report the stock price went up 6.383%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Among the largest hedge funds holding Lyell Immunopharma’s share is Woodline Partners LP. It holds Lyell Immunopharma’s shares valued at 30K.
---
Lyell Immunopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.67 (135.26% Upside)
$3.67 (135.26% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 223.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.66%
12-Months-Change
Fundamentals
Return on Equity
-32.26%
Trailing 12-Months
Asset Growth
-21.69%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
---
LYEL Stock 12 Month Forecast
Average Price Target
$3.67
▲(135.26% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+3.40%
reiterated a buy rating 3 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +3.40% per trade.
---